Meeting
2022 ASCO Genitourinary Cancers Symposium
Association of leucocyte levels in urine with tissue PD-L1 status and immune infiltration into basal bladder cancer subtype in the prospective real-world clinicopathological register trial Bladder BRIDGister.
Authors
Thorsten Ecke
HELIOS Hospital, Bad Saarow, Germany
Thorsten Ecke , Frank Friedersdorff , Elke Veltrup , Ergin Kilic , Roland Hake , Sebastian Eidt , Jenny Roggisch , Stefan Koch , Ralph M. Wirtz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 560)
DOI
10.1200/JCO.2022.40.6_suppl.560
Abstract #
560
Poster Bd #
K3
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Presence of CD8+ cytotoxic T-cells in proximity to tumor cells, TIM3, CTLA-4 and prognostic implications for muscle-invasive urothelial cancer.
First Author: Nicolaus F. Debatin
Poster
2022 ASCO Annual Meeting
LAG3 transcriptomic expression correlates with high levels of PD-1, PD-L1, PD-L2, and CTLA-4 checkpoints and with high tumor mutational burden across cancers.
First Author: Jacob J. Adashek
Poster
2020 ASCO Virtual Scientific Program
A phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi sarcoma (CKS).
First Author: Alona Zer
Poster
2020 ASCO Virtual Scientific Program
Targetable immune checkpoint molecules may be significantly differentially expressed in minority ethnicities.
First Author: Jacob J. Adashek